DEF 14A: Ultragenyx Pharmaceutical Inc. Announces Details for 2024 Annual Stockholders Meeting, Including Executive Compensation and Director Elections

Ultragenyx Pharmaceutical Inc. has released its proxy statement detailing proposals for the upcoming annual stockholders meeting, including director elections, approval of an incentive plan, and executive compensation.

Summary

• Ultragenyx Pharmaceutical Inc. has announced details for its Annual Meeting of Stockholders to be held virtually on June 18, 2024.
• The meeting will address the election of three Class II directors, approval of the Amended and Restated 2023 Incentive Plan (A&R 2023 Plan), ratification of Ernst & Young LLP as the independent registered public accounting firm, and an advisory vote on executive compensation.
• In 2023, Ultragenyx achieved \$434 million in total revenue, a 20% increase from \$363 million in 2022.
• Crysvita sales increased by 77% in countries where Ultragenyx leads commercialization, reaching \$76 million.
• Global revenue from Dojolvi increased by 27% to \$71 million, and Mepsevii revenue increased by 48% to \$30 million.
• The A&R 2023 Plan seeks stockholder approval for an additional 4.0 million shares of common stock to be available for issuance.
• The company's three-year average burn rate is 4.95%.
• The aggregate dollar value of equity-based and cash compensation granted to any one non-employee director during any fiscal year will not exceed \$900,000, with up to \$1,500,000 to be permitted for a non-employee director in the fiscal year he or she first joins our Board or is first designated as Chairman of our Board or Lead Director.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, highlighting revenue growth and clinical progress. However, it also acknowledges challenges and risks, resulting in a moderately positive sentiment score.

Positives

• The company experienced significant revenue growth across its key products.
• The proposed A&R 2023 Plan includes several corporate governance best practices, such as no repricing of stock options without stockholder approval and a clawback provision.
• The company is committed to corporate responsibility, focusing on innovation, patients, people, communities, planet, and governance.
• The company has a Director Resignation Policy in place.

Negatives

• The company's 2022 revenue-based PSUs were forfeited due to not achieving the threshold level of performance.
• The company's voluntary employee turnover rate in 2023 was 10.5%, which is below the U.S. and global averages for our industry according to benchmark reports from Aon/Radford.

Risks

• The company's success depends on the development and commercialization of treatments for rare diseases, which can be subject to regulatory and clinical trial risks.
• The company faces competition from other therapies and products in the biopharmaceutical industry.
• The company's future operating results and financial performance are subject to various risks and uncertainties.

Future Outlook

The company anticipates developing six to seven clinical therapies with the potential to reach up to 150,000 patients.

Management Comments

• Emil D. Kakkis, M.D., Ph.D., President and Chief Executive Officer, looks forward to speaking with stockholders at the Annual Meeting.

Industry Context

The document highlights Ultragenyx's position in the rare disease medicine sector, emphasizing its commitment to developing novel therapies for diseases with limited or no treatment options. It also mentions the company's involvement in industry coalitions and advocacy efforts to influence policy and regulation in the rare disease space.

Comparison to Industry Standards

• The document benchmarks executive compensation against a peer group of 21 companies in the biopharmaceutical and biotechnology industries, including ACADIA Pharmaceuticals Inc., Biomarin Pharmaceutical Inc., and Jazz Pharmaceuticals plc.
• The peer group was selected based on factors such as emphasis on orphan pharmaceutical products, comparable market capitalizations (between \$2 billion and \$16 billion), revenue (between \$200 million and \$1 billion), and employee headcount (between 300 and 3,000 employees).
• The company's voluntary employee turnover rate in 2023 was 10.5%, which is below the U.S. and global averages for our industry according to benchmark reports from Aon/Radford.

Corporate Governance

Stakeholder Impact

• Shareholders are provided with information to make informed decisions on key proposals.
• Employees are impacted by compensation policies and benefit plans.
• Patients benefit from the company's commitment to developing novel therapies for rare diseases.
• Communities benefit from the company's support of initiatives that provide impactful resources for the rare disease community, public health and access to care, Science, Technology, Engineering, the Arts and Mathematics (STEAM) education, and local, at-risk communities.

Next Steps

• Stockholders are urged to vote via the internet or by completing and returning the proxy card.
• The company will file a Form S-8 with the SEC following the Annual Meeting during the second or third quarter that covers the additional shares reserved for issuance under the A&R 2023 Plan.

Key Dates

Keywords

Ultragenyx, proxy statement, annual meeting, executive compensation, director election, incentive plan, revenue, Crysvita, Dojolvi, Mepsevii, rare diseases, corporate governance